FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Silva Francisco		 2. Issuer Name and Ticker or Trading Symbol

BioRestorative Therapies, Inc. [ BRTX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
VP of Research and Development
(Last)          (First)          (Middle)

40 MARCUS DRIVE		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/23/2020
(Street)

MELVILLE, NY 11747
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/23/2020  J(12)  8375671 A (12)8431629 D  
Common Stock         12116 I IRA 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option $.75            (1)4/4/2021 Common Stock 4000  4000 D  
Stock Option $.75           6/24/2011 6/23/2021 Common Stock 150  150 D  
Stock Option $.75           11/16/2011 11/15/2021 Common Stock 1000  1000 D  
Stock Option $.75            (2)2/9/2022 Common Stock 2000  2000 D  
Stock Option $.75            (3)5/2/2022 Common Stock 5500  5500 D  
Stock Option $.75            (4)12/7/2022 Common Stock 4000  4000 D  
Stock Option $.75            (5)10/4/2023 Common Stock 5000  5000 D  
Stock Option $.75            (6)2/18/2024 Common Stock 12500  12500 D  
Stock Option $.75           3/12/2014 3/11/2024 Common Stock 2000  2000 D  
Stock Option $.75           4/14/2014 5/2/2022 Common Stock 2000  2000 D  
Stock Option $.75            (7)10/23/2024 Common Stock 37500  37500 D  
Stock Option $.75            (8)9/4/2025 Common Stock 25000  25000 D  
Stock Option $.75            (9)6/10/2026 Common Stock 60000  60000 D  
Stock Option $.75            (10)7/12/2027 Common Stock 80000  80000 D  
Stock Option $.75            (11)10/29/2028 Common Stock 100000  100000 D  
Explanation of Responses:
(1) The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012.
(2) The option is exercisable to the extent of 1,000 shares on each of February 10, 2012 and February 10, 2013.
(3) The option is exercisable to the extent of 500 shares on each of May 3, 2013, May 3, 2014 and May 3, 2015, became exercisable to the extent of 1,000 shares based on the satisfaction of certain conditions and is exercisable to the extent of 3,000 shares subject to the satisfaction of certain conditions.
(4) The option is exercisable to the extent of 2,000 shares on each of December 7, 2012 and December 7, 2013.
(5) The option is exercisable to the extent of 2,500 shares on each of October 4, 2013 and October 4, 2014.
(6) The option is exercisable to the extent of 4,167 shares on each of February 18, 2014 and February 18, 2015, and 4,166 shares on February 18, 2016.
(7) The option is exercisable to the extent of 12,500 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017.
(8) The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018.
(9) The option is exercisable to the extent of 20,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019.
(10) The option is exercisable to the extent of 26,667 shares on each of July 12, 2018 and July 12, 2019, and 26,666 shares on July 12, 2020.
(11) The option is exercisable to the extent of 33,334 shares on October 29, 2019, and 33,333 shares on each of October 29, 2020 and October 29, 2021.
(12) Shares acquired from Issuer pursuant to amended joint plan of reorganization of Issuer (the "Plan"). Pursuant to the Plan, 100 shares of common stock were issued for each dollar of allowed unsecured claim.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Silva Francisco
40 MARCUS DRIVE
MELVILLE, NY 11747		X
VP of Research and Development
Signatures
/s/ Francisco Silva11/23/2020
**Signature of Reporting PersonDate